research use only
Cat.No.S7753
| Related Targets | HDAC Caspase Proteasome Secretase MMP HCV Protease Cysteine Protease DPP Tyrosinase HIV Protease |
|---|---|
| Other Glutaminase Inhibitors | Telaglenastat (CB-839) JHU-083 GK921 LDN-27219 JHU395 6-Diazo-5-oxo-L-norleucine (Diazooxonorleucine) UPGL00004 IACS-6274 Glutaminase C-IN-1 Sirpiglenastat (DRP-104) |
| Cell Lines | Assay Type | Concentration | Incubation Time | Formulation | Activity Description | PMID |
|---|---|---|---|---|---|---|
| MDA-MB-231 cell | Cytotoxicity assay | 6 days | Cytotoxicity against human MDA-MB-231 cells measured on 6th day by hemocytometry, IC50=2.61 μM | 26988803 | ||
| MDA-MB-231 | Growth inhibition assay | 72 hrs | Growth inhibition of human MDA-MB-231 cells after 72 hrs by MTS assay, IC50 = 6.8 μM. | 28609101 | ||
| Aspc-1 | Growth inhibition assay | 72 hrs | Growth inhibition of human Aspc-1 cells after 72 hrs by MTS assay, IC50 = 10.2 μM. | 28609101 | ||
| HCC827 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human erlotinib-resistant HCC827 cells assessed as growth inhibition after 48 hrs by CCK8 assay, IC50 = 42.4 μM. | 28174105 | ||
| HT1080 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human HT1080 cells assessed as growth inhibition after 48 hrs by CCK8 assay, IC50 = 47.72 μM. | 28174105 | ||
| Click to View More Cell Line Experimental Data | ||||||
|
In vitro |
DMSO
: 50 mg/mL
(95.29 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 524.68 | Formula | C24H24N6O2S3 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 314045-39-1 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | C1=CC=C(C=C1)CC(=O)NC2=NN=C(S2)CCSCCC3=NN=C(S3)NC(=O)CC4=CC=CC=C4 | ||
| Targets/IC50/Ki |
Glutaminase GLS1 (KGA)
0.16 μM
|
|---|---|
| In vitro |
BPTES inhibits glutaminase activity expressed in human kidney cells with IC50 of 0.18 μM, and inhibits glutamate efflux by microglia with IC50 of 80-120 nM. This compound preferentially slows cell growth in D54 cells with mutant IDH1. It also inhibits glutaminase activity, lowers glutamate and α-KG levels, and increases glycolytic intermediates. This chemical (10 μM) inhibits cell growth of mHCC 3–4 cells derived from LAP/MYC tumors. It also inhibits growth of a MYC-dependent P493 cells by blocking DNA replication, leading to cell death and fragmentation. |
| Kinase Assay |
Glutaminase Inhibition: Cell Free Assay
|
|
Assay plates are prepared containing 2 μL test compound in DMSO/well. The enzyme is diluted to 1 unit (liver) or 0.8 unit (kidney)/100 μL in glutaminase assay buffer, and 100 μL diluted enzyme is added to each well of the assay plate by Multidrop. The contents are mixed by shaking at full speed for 1 min on TiterMix 100. The plates are preincubated at room temperature (RT) for 20 min to allow binding of test compounds to glutaminase, and 50 μL glutamine solution (7 mM in assay buffer) is added to each well by Multidrop. The contents are shaken at full speed for 30 sec on TiterMix 100, and the plates are then incubated at RT for 60 min (liver) or 90 min (kidney). To stop the reactions, 20 μL HCl (0.3 N) is added to each well by Multidrop and mixed immediately by shaking for 30 sec on TiterMix 100. For quantification, glutamate (formed by glutaminase-catalyzed hydrolysis of glutamine) is oxidized to 2-oxoglutarate by a second enzyme, glutamate dehydrogenase (GDH), with the concomitant production of the reduced form of nicotinamide adenine dinucleotide (NADH). Reduction of nitro blue tetrazolium (NBT) in the assay solution by NADH, catalyzed by phenazine methosulphate (PMS), results in the formation of a blue-purple formazan. The absorption of formazan at 540 nm is linearly proportional to the concentration of glutamate up to 200 μM. NBT/GDH reagent (50 μL) is added to each well by Multidrop and mixed by shaking for 30 sec on TiterMix 100, and the plates are incubated at RT for 20 min to allow color formation by the GDH reaction. Glutamate concentration is determined from formazan concentration as determined by reading OD540 nm on a SpectraMax 340.
|
|
| In vivo |
In LAP/MYC mice, BPTES (12.5 mg/kg, i.p.) prolongs survival with no significant effects on MYC, GLS, or GLS2 levels. This compound (200 μg/mouse, i.p.) also inhibits tumor cell growth in mice harboring P493 tumor xenografts. |
References |
|
| Methods | Biomarkers | Images | PMID |
|---|---|---|---|
| Western blot | γH2AX c-Myc / KLF4 / SOX2 / OCT4 / NANOG / GLS1 |
|
29107960 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.